Surgical Outcomes and Early Postoperative Complications in Locally Advanced Gastric Cancer

Yıl 2011, , 2 - 3, 01.08.2011

Lütfi Doğan Niyazi Karaman Sevinç Hüseyinova Cihangir Özaslan

https://doi.org/10.5505/aot.2011.29392

Öz

OBJECTIVE: In Western world, 60 to 65% of the gastric cancer cases are in locally advanced stage at the time of diagnosis and in these patients, extended resections may increase the risk of complications. The aim of this study was to investigate the resectability rates and to determine early morbidity and mortality rates after resections for locally advanced gastric cancer.METHODS: Consecutive non-metastatic locally advanced gastric cancer patients treated between October 2002 and September 2006 were included in this retrospective exploratory analyses study.RESULTS: One hundred and ten patients (49.8%) had additional organ resection due to adjacent organ involvement. R0 resection was achieved in 181 patients (82%), R1 resection in 29 patients (13%), and R2 resection in 11 patients (5%). The morbidity and mortality rates of the all series were 21,7% and 4.5% respectively. More than two additional organ resections (p=0.001), eryhtrocyte transfusions of more than 2 units (p=0.001) and low total protein levels (p=0.008) were determined as the parameters which increase complication rates according to multivariate analysis. The parameters which increase mortality rates were as follows; having two or more additional organ resections (p=0.001), cardiovascular and respiratory comorbidities (p=0.002) and total gastrectomy (p=0.028).CONCLUSION: Additional organ resection rates of the patient with locally advanced gastric cancers that not given neo-adjuvant treatment is high and this occurance increases the morbidity and mortality rates. Altough total gastrectomy has been found to be a factor for increased mortality in locally advanced gastric cancer, D2 dissection is safe for these patients

Anahtar Kelimeler

complications, locally advanced gastric cancer, mortality, morbidity

Lokal İleri Evre Mide Kanserinde Cerrahi Sonuçlar ve Erken Postoperatif Komplikasyonlar

Öz

AMAÇ: Batı ülkelerinde saptanan mide kanserlerinin %60-65'i tanı anında lokal ileri evrededirler. Bu hastalara uygulanan genişletilmiş rezeksiyonlar komplikasyon riskini arttırabilir. Bu çalışmanın amacı lokal ileri evre mide kanserlerinde rezektabilite, erken dönem mortalite ve morbidite oranlarını saptamaktır. YÖNTEMLER: Ocak 2002 ile Eylül 2006 tarihleri arasında rezeksiyon uygulanan non-metastatik, lokal ileri evre mide kanserli hastalarımız geriye dönük olarak incelendi. BULGULAR: Komşu organ invazyonu nedeni ile 110 hastaya (%49.8) ek organ rezeksiyonu uygulanmıştı. Yüzseksen bir hastaya (%82) R0, 29 hastaya (%13) R1 ve 11 hastaya (%5) R2 rezeksiyon yapılabilmişti. Tüm serinin morbidite ve mortalite oranları sırasıyla %21.7 ve % 4.5 olarak bulundu. İkiden fazla ek organ rezeksiyonu (p=0.001), 2 üniteden fazla kan transfüzyonu (p=0.001) ve düşük protein seviyeleri (p=0.008) multivaryant analizlerde komplikasyon oranlarını arttıran parametreler olarak saptandı. İki veya daha fazla ek organ rezeksiyonu (p=0.001), kardiyovasküler ve respiratuar komorbidite (p=0.002) ve total gastrektomi uygulanması (p=0.028) mortaliteyi arttıran faktörler olarak bulundu. SONUÇ: Neo-adjuvan tedavi uygulanmayan lokal ileri evre mide kanserli hastalarda ek organ rezeksiyonu oranları yüksektir ve bu durum morbidite ve mortalite oranlarını arttırır. Total gastrektomi mortaliteyi arttıran bir faktör olarak belirlenmiş ancak D2 diseksiyonun bu hastalarda güvenle uygulanabileceği sonucuna varılmıştır.

Anahtar Kelimeler

komplikasyon, lokal ileri evre mide kanseri, mortalite, morbidite

Kaynakça

• the most common procedures in this group.
• Two or more additional organ resections were
• determined as a factor that increases mortality,
• morbidity and anastomotic dehiscence in
• multivariate analysis. In a study by Ozer et al.,
• more than two additional organ resections are
• also related to morbidity (13).
• Splenectomy was added to the primary
• procedures of 87 patients. Only 9 of the
• splenectomies were performed for iatrogenic
• injuries. The other reasons for splenectomies were
• implantations on splenic capsule and lymph
• node involvement in splenic hilus. tumoral
• In the last few years, the results of
• different neo-adjuvant chemotherapy regimes
• given to the patients with radiologically proven
• invasion to the adjacent structures have been
• published in the literature. In a series by Wang
• et al., 87 patients with T4 tumor treated with
• neoadjuvant chemotherapy and operated with
• 7% R0 resection rate without any need for
• adjacent organ resection (24). In a series of 49
• patients by Ott et al., this rate was 76% (25).
• Seventeen of 18 patients presented by Newman
• (26)and 19 of 22 patients presented by Guo
• (27) could have been operated with R0
• resection without requiring adjacent organ
• resection. In none of these studies, neoadjuvant chemotherapy
• operative morbidity and mortality. In our series
• of locally advanced tumors, not treated with
• neo-adjuvant chemotherapy, additional organ
• resection had to be applied in 50% of the cases.
• At the same time our R1 and R2 resection rates
• are also high (13% and 5%). In literature, there
• are some other studies stating that R0 resection
• rates of locally advanced gastric tumors, not
• treated with neo-adjuvant chemotherapy, are
• low (28). But now, there is increasing evidence
• that neo-adjuvant chemotherapy potentially
• down-stages the tumor and therefore may
• improve the resectability rate with negative
• surgical margins (29,30). to increase
• In literature, the morbidity and
• mortality rates for locally advanced gastric
• cancer surgery changes between 25-30% and
• 10% respectively (31,32). The mortality rate
• for earlier stages of gastric cancer is 2-3%
• (13). Similarly, neo-adjuvant treatment may
• decrease morbidity and mortality rates by
• decreasing the need for additional organ
• resection (16). Patient characteristics can effect mortality and morbidity rates besides the surgical procedures. Advanced age, male sex, blood loss during operation, low total protein and hemoglobin levels and duration of operation were determined as a factors which effect the morbidity rates negatively (33-36).
• Age, hemoglobin and lymphocyte counts were
• not found as significant factors for the
• morbidity in our series. In multivariate
• analysis, low total protein levels and blood
• transfusions of more than 2 units were
• significant factors for the morbidity, whereas
• cardiac and respiratory comorbidities were
• significant for the mortality. Low total protein levels
• necessity lead to immunosuppression and
• problems in wound healing. Blood transfusions
• increase intracellular adhesion molecules and
• this may be the reason for high predisposition
• to infective complications. In patients with
• locally advanced gastric cancers, the need for
• blood transfusion either preoperatively or
• postoperatively was also high. Cardiac and
• respiratory problems are the most important
• causes of early mortality in upper abdominal surgery. blood transfusion Conclusion
• Additional organ resection rates of the patient
• with locally advanced gastric cancers that not
• given neo-adjuvant treatment is high and this
• occurrence increases the morbidity and
• mortality rates. While total gastrectomy was
• preferred surgical option for locally advanced
• gastric cancers, D2 dissection was used less
• frequently in this series of patients.
• If the subtotal gastrectomy is the
• suitable procedure according to the tumor
• localization, surgeon should not insist on
• performing total gastrectomy. D2 dissection is
• a safe procedure in the treatment of locally
• advanced gastric carcinoma. Gastric cancer
• patients who have cardiac and respiratory
• comorbidities must be prepared to surgery
• carefully. Immunity and nutritional levels of
• the patients must be evaluated preoperatively.
• Conflict of Interest: None.
• Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47
• Roder JD, Böttcher K, Busch R, Wittekind C, Hermanek P, Siewert JR. Classification of regional lymph node metastases from gastric carcinoma. Cancer 1998;82:621-31
• Winn RJ, Mc Clure J. The NCCN clinical practice guidelines in oncology. Gastric cancer. In: Journal of the National Comprehensive Cancer Network 2003;1:28-9
• D'Ugo D, Persiani R, Zoccali M, et al. Surgical issues after neoadjuvant treatment for gastric cancer. Eur Rev Med Pharmacol Sci 2010;14:315-9
• Macintyre IM, Akoh JA. Improving survival in gastric cancer: Review of operative mortality in English language publications from 1970. Br J Surg 1991;78:771-6
• Gouzi JL, Huguier M, Fagniez PL, t al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 1989;209:162-6
• Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer. Five year survival rates in a multicenter randomized Italian trial. Ann Surg 1999;230:170-8
• Onate-Ocana LF, Cortes-Cardinas SA, Aiello- Crocifoglio V, Mondragon-Sanchez R, Ruiz-Molina JM. Preoperative multivariate prediction of morbidity after gastrectomy for adenocarcinoma. Ann Surg Oncol 2000;7:281-8
• Nanthakumaran S, Fernandes E, Thompson AM, Rapson T, Gilbert FJ, Park KG. Morbidity and mortality rates following gastric cancer surgery and contiguous organ removal, a population based study. Eur J Surg Oncol 2005;31:1141-4
• Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph node dissection for gastric cancer. N Engl J Med 1999;340:908-14
• Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised 1996;347:995-9 surgical trial. Lancet
• Cuschieri A, Weeden S, Fielding J et al. Patients survival after D1 and D2 resection for gastric cancer: long term results of the MRC randomised surgical trial. Br J Cancer 1999;79:1522-30
• Ozer I, Bostanci EB, Orug T, Ozogul YB, Ulas M. Surgical outcomes and survival after multiorgan resection for locally advanced gastric cancer. Am J Surg. 2009;198:25-30
• Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Achieving RO resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection? J Am Coll Surg. 2002;194:568-77
• Carboni F, Lepiane P, Santoro R, Lorusso R, Mancini P, Sperduti I. Extended multiorgan resection for T4 gastric carcinoma: 25-year experience.
• J Surg Oncol 2005;90:95-100
• Lordick F, Siewert JR. Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer 2005;8:78-85
• Kodama I, Takamiya H, Mizutani K, Ohta J, Aoyagi K, Kofuji K. Gastrectomy with combined resection of other organs for carcinoma of the stomach with invasion to adjacent organs: clinical efficacy in a retrospective study. J Am Coll Surg 1997;184:16-22
• Dhar DK, Kubota H, Tachibana M, Kinugasa S, Masunaga R, Shibakita M. Prognosis of T4 gastric carcinoma patients: an appraisal of aggressive surgical treatment. J Surg Oncol 2001;76:278-82
• Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg 2002;236:159-65
• Kitamura K, Nishida S, Ichikawa D et al. No survival benefit from combined pancreaticosplenectomy and total gastrectomy for gastric cancer. Br J Surg 1999;86:119-22
• Lo SS, Wu CW, Shen KH, Hsieh MC, Lui WY. Higher morbidity and mortality after combined total gastrectomy and pancreaticosplenectomy for gastric cancer. World J Surg 2002;26:678-82
• Isozaki H, Tanaka N, Tanigawa N, Okajima K. Prognostic factors in patients with advanced gastric cancer with macroscopic invasion to adjacent organs treated with radical surgery. Gastric Cancer 2000;3:202-10
• Colen KL, Marcus SG, Newman E, Berman RS, Yee H, Hiotis SP. Multiorgan resection for gastric cancer: intraoperative and computed tomography assessment of locally advanced disease is inaccurate. J Gastrointest Surg 2004;8:899-902
• Wang LB, Shen JG, Xu CY. Neoadjuvant chemotherapy versus surgery alone for locally advanced gastric cancer: a retrospective comparative study. Hepatogastroenterology 2008;55:1895-8
• Ott K, Sendler A, Becker K, et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective 2003;6:159-67 study. Gastric Cancer
• Newman E, Marcus SG, Potmesil M, et al. Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer. J Gastrointest Surg 2002;6:212-23
• Guo MG, Zheng Q, Cheng Z, Wang Y, Feng CN, Yang Z. The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer. Surg Oncol 2010;19:1-3
• Kim JH, Jang YJ, Park SS, et al. Surgical outcomes and prognostic factors for T4 gastric cancers. Asian J Surg 2009;32:198-204
• Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11- 20
• Mezhir JJ, Tang LH, Coit DG. Neoadjuvant therapy of locally advanced gastric cancer. J Surg Oncol 2010;101:305-14
• Bloechle C, Izbicki JR, Limmer J, Kühn R, Hosch SB, Busch C. Multi-visceral resection for locally advanced gastric cancer. Acta Chir Belg 1995;95:72- 5
• Shchepotin IB, Chorny VA, Nauta RJ, Shabahang M, Buras RR, Evans SR. Extended surgical resection in T4 gastric cancer. Am J Surg 1998;175:123-6
• Viste A, Haugstvedt T, Eide GE, Soreide O. Postoperative complications and mortality after surgery for gastric cancer. Ann Surg 1988;207:7-13
• Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 2004;22:2069-77
• Kodera Y, Sasako M, Yamamato S, Sano T, Nashimoto A, Kurita A. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg 2005;92:1103-9
• Ichikawa D, Kurioka H, Yamaguchi T, et al. Postoperative complications following gsatrectomy for during Hepatogastroenterology 2004;51:613-7 the last decade.